Critical Survey: GeneLink (OTCMKTS:GNLKQ) versus Celcuity (NASDAQ:CELC)

Celcuity (NASDAQ:CELC) and GeneLink (OTCMKTS:GNLKQ) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Institutional & Insider Ownership

63.3% of Celcuity shares are owned by institutional investors. 15.8% of Celcuity shares are owned by insiders. Comparatively, 14.2% of GeneLink shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Celcuity and GeneLink’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-62.66%	-39.78%
GeneLink	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Celcuity and GeneLink, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	0	0	6	1	3.14
GeneLink	0	0	0	0	0.00

Celcuity currently has a consensus price target of $29.17, suggesting a potential upside of 155.40%. Given Celcuity’s stronger consensus rating and higher probable upside, analysts plainly believe Celcuity is more favorable than GeneLink.

Earnings and Valuation

This table compares Celcuity and GeneLink”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$63.78 million	($2.61)	-4.38
GeneLink	N/A	N/A	N/A	N/A	N/A

Summary

Celcuity beats GeneLink on 6 of the 8 factors compared between the two stocks.

About Celcuity

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

About GeneLink

GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was founded in 1994 and is based in Orlando, Florida.